Creative Compounds Recalls Ceftazidime Syringes Due to Sterility Concerns
Oregon Compounding Centers is recalling Ceftazidime syringes because quality control issues observed during an FDA inspection may compromise sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of sterility assurance in an injectable drug, which poses a significant risk of serious injury or infection.
Plain-English summary
Oregon Compounding Centers, Inc. dba Creative Compounds is recalling 12 syringes of CEFTAZIDIME, 2.25mg/0.1mL, Injectable. The specific lot number is 20140905@33, and the discard date is 10/20/2014. The product was distributed in Oregon and Washington.
The recall was initiated due to a lack of sterility assurance. During a recent FDA inspection, quality control procedures were observed that present a potential risk to sterility assurance for all lots of sterile products compounded by the pharmacy that are not expired.
Consumers and healthcare providers should stop using the affected product and contact the recalling firm for further instructions or a refund.
The recalled product
- Product
- CEFTAZIDIME, 2.25mg/0.1mL, Injectable, 0.2 mL plastic syringe, RX, Creative Compounds, Wilsonville, OR 97070
- Category
- Drug — Injectable
- Affected units
- 12
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 20140905@33
- discard date: 10/20/2014
Distribution
Part of a larger recall action
This product is one of 56 recalled by Oregon Compounding Centers, Inc. dba Creative Compounds under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Oregon Compounding Centers, Inc. dba Creative Compounds
See all →- SevereGanciclovir Syringes Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Papaverine Injectable Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Injectable Methycobalamin Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Vitamin B Complex Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Copper Sulfate Injectable Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
Same hazard · sterility assurance
See all →- HighArrowhead DE LLC Recalls Arrow-LOK Implants Due to Sterility Assurance Concerns
FDA (Devices) · 2026-08-26
- SevereChloraPrep One-Step Applicators Recalled for Potential Packaging Seal Defects
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereChloraPrep One-Step Applicators Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2026-07-08
- SevereArrow access trays and PSI kits contain recalled supplier drugs
FDA (Devices) · 2026-06-24
Similar recalls
- HighCeftazidime Intravitreal Solution Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- SevereSpecialty Medicine Compounding Pharmacy Recalls Ceftazidime Ophthalmic Solution
FDA (Drugs) · 2014-01-22
- HighCeftazidime Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01
- HighCeftazidime Sterile Ophthalmic Solution Lacks Sterility Assurance
FDA (Drugs) · 2022-02-02
- SevereEdge Pharma Recalls Ceftazidime Sterile Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2021-01-27
- SevereLincare Recalls Ceftazidime IV Bags Due to Sterility Concerns
FDA (Drugs) · 2015-07-08